A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib

European Journal of Haematology

Volumn 86, Issue 6, 2011, Pages 531-535

  Mital, Andrzej ^a   Piskorz, Anna ^a   Lewandowski, Krzysztof ^a   Wasag, Bartosz ^a   Limon, Janusz ^a   Hellmann, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Imatinib; KIT gene mutation; Mast cell leukaemia

Indexed keywords

IMATINIB; TRYPTASE;

ADULT; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW BIOPSY; BONE PAIN; CASE REPORT; CELL INFILTRATION; CELL PROLIFERATION; DRUG RESPONSE; ENZYME BLOOD LEVEL; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; KIT GENE; MAST CELL LEUKEMIA; MUSCLE HYPOTONIA; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; LEUKEMIA, MAST-CELL; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 79955998389     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01598.x     Document Type: Article

References (25)

1. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, Bennett JM, Metcalfe DD. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003;122:695-717.
2. Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics and current options for therapy. Leuk Lymphoma 2005;46:35-8.
3. Hartmann K, Metcalfe DD. Pediatric mastocytosis. Hematol Oncol Clin North Am 2000;14:625-40.
4. Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 2008;3:E1906.
5. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006;19:595-615.
6. Donker ML, van Doormaal J, van Doormaal FF, Kluii PM, van der Veer E, de Monchy JGR, Kema IP, Kluin-Nelemans HC. Biochemical markers predictive for bon marrow involvement in systemic mastocytosis. Haematologica 2008;93:120-3.
7. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007;131:784-91.
8. Horny H-P, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P. Mastocytosis. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:54-63.
9. Orfao A, Garcia-Montero A, Sanches L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
10. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. The KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4.
11. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-24.
12. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686-92.
13. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-5.
14. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NCP, Cavenagh JD. A novel 5090 mutation of KIT identified in familial mastocytosis: in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-8.
15. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-25.
16. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:1481-4.
17. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
18. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumors. Histopathology 2008;53:245-66.
19. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53.
20. Hauswirth AW, Siminitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, Valent P. Response to therapy with interferon α-2b and prednisolone in aggressive systemic masocytosis: report of five cases and review of the literature. Leuk Res 2004;28:249-57.
21. Kluin-Nelemans HC, Oldhoff JM, van Doormaal JJ, van't Wout JW, Verhoef G, Gerrits WB. Cladribine therapy for systemic mastocytosis. Br J Rheumatol 1997;36:393-6.
22. Tefferi A, Verstovsek S, Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica 2008;3:6-9.
23. Purtill D, Cooney J, Sinniah R, Carnley B, Cull G, Augustson B, Canell P. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol 2008;80:456-8.
24. 816V and other activating c-KIT mutations. J Invest Dermatol 2010;130:804-15.
25. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection of imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 2006;42:1093-103.